Explore

Reuters Reuters
Explainer-What to know about the multistate Salmonella outbreak in the US

Explainer-What to know about the multistate Salmonella outbreak in the US

Aug 7 (Reuters) - U.S. health authorities are currently investigating a multistate outbreak of Salmonella Javiana infections linked to fresh jalapeno peppers. The investigation is being carried out jointly by the Centers for Disease Control and Prevention (CDC) and the U.S.
Rapid Read Rapid Read
FDA Approves Moderna's mRNA Flu Vaccine for Older Adults, Offering New Protection

FDA Approves Moderna's mRNA Flu Vaccine for Older Adults, Offering New Protection

The Food and Drug Administration (FDA) has approved Moderna's mRNA-based flu vaccine, mFlusiva, marking a significant advancement in flu prevention for adults aged 50 and older. This approval is the first of its kind for a non-COVID-related mRNA vaccine in the United States. The vaccine is initially approved for individuals aged 50 to 64, with further studies planned for those over 65. Clinical trials demonstrated that mFlusiva is 26.6% more effective than traditional flu vaccines. Moderna plans to make the vaccine available at select retailers soon, as other flu vaccines are already arriving in pharmacies for the upcoming vaccination season.
Trendline Trendline
Tandem Diabetes Care Reports Q2 2026 Financial Results, Highlights Strategic Progress

Tandem Diabetes Care Reports Q2 2026 Financial Results, Highlights Strategic Progress

Tandem Diabetes Care Reports Q2 2026 Financial Results, Highlights Strategic Progress
Rapid Read Rapid Read
FDA Approves First mRNA-Based Flu Vaccine by Moderna for Adults Over 50

FDA Approves First mRNA-Based Flu Vaccine by Moderna for Adults Over 50

The U.S. Food and Drug Administration (FDA) has approved the first mRNA-based flu vaccine, mFLUSIVA, developed by Moderna, for adults aged 50 and older. This approval is a significant milestone in the use of mRNA technology beyond COVID-19 vaccines. The vaccine was found to be 27% more effective than standard flu shots in clinical trials involving over 40,000 participants. The mRNA platform allows for quicker production and potentially better matching of vaccines to circulating flu strains. Despite initial hesitance from the FDA and the Department of Health and Human Services, the vaccine's approval reflects its potential to address public health challenges.
Rapid Read Rapid Read
FDA Approves First mRNA Flu Vaccine for U.S. Adults Over 50

FDA Approves First mRNA Flu Vaccine for U.S. Adults Over 50

The Food and Drug Administration (FDA) has approved mFlusiva, the first mRNA-based influenza vaccine for adults in the United States. Developed by Moderna, the vaccine is approved for adults over 50, with accelerated approval for those aged 65 and over based on immune response data. The approval comes as mRNA technology, which was pivotal in COVID-19 vaccine development, is being adapted for flu vaccines to improve efficacy against emerging strains. The vaccine demonstrated a 26.6% higher effectiveness compared to traditional flu vaccines in recent trials. However, access for those over 65 is contingent on ongoing clinical trials assessing specific needs for this demographic.
Rapid Read Rapid Read
Jalapeño Salmonella Outbreak Traced to Mexican Farm and U.S. Distributor

Jalapeño Salmonella Outbreak Traced to Mexican Farm and U.S. Distributor

A multistate salmonella outbreak linked to jalapeño peppers has been traced back to a grower in Sinaloa, Mexico, and distributed by Coast Citrus Distributors in the U.S. At least 345 people across 27 states have fallen ill, with 36 hospitalizations reported. The outbreak has primarily affected patrons of Mexican-style restaurants, including Chipotle and Qdoba, which have since removed jalapeños from their menus. The FDA is investigating whether the contaminated peppers reached grocery stores, while Mexican health officials have initiated an investigation at a packing plant in Nuevo Leon.
Rapid Read Rapid Read
FDA Approves First mRNA-Based Flu Vaccine by Moderna

FDA Approves First mRNA-Based Flu Vaccine by Moderna

The FDA has approved Moderna's mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older. The vaccine demonstrated a 27% higher efficacy compared to standard flu shots in trials with over 40,000 participants. Moderna's mRNA technology allows for quicker updates to match circulating flu strains, potentially improving vaccine effectiveness. The approval process faced initial resistance from the FDA but was eventually granted following a unanimous vote by an independent advisory panel.
Palm Beach Post Palm Beach Post
Quick answers to cyclospora questions. 5 tips to safely eating lettuce

Quick answers to cyclospora questions. 5 tips to safely eating lettuce

We rounded up answers to common questions in this quick-hit guide about cyclospora, including five tips on how to safely eat lettuce during outbreaks.
AP News AP News
Jalapeños linked to a US salmonella outbreak are tracked to a Mexican farm and a distributor

Jalapeños linked to a US salmonella outbreak are tracked to a Mexican farm and a distributor

Federal officials have traced a multistate salmonella outbreak to jalapeño peppers from a grower in Sinaloa, Mexico
Trendline Trendline
GRAIL's Galleri Test Shows Promise in Early Cancer Detection

GRAIL's Galleri Test Shows Promise in Early Cancer Detection

GRAIL's Galleri Test Shows Promise in Early Cancer Detection
Rapid Read Rapid Read
FDA Approves ORZEYFUL for Narcolepsy Type 1, Offering New Treatment Options

FDA Approves ORZEYFUL for Narcolepsy Type 1, Offering New Treatment Options

The U.S. Food and Drug Administration (FDA) has approved ORZEYFUL, an oral orexin receptor 2 agonist, for treating narcolepsy type 1 (NT1) in adults. Developed by Takeda, ORZEYFUL is the first medication in the U.S. to address the full spectrum of NT1 symptoms, including excessive daytime sleepiness and cataplexy. Clinical trials demonstrated significant improvements in patients compared to those on a placebo. The approval marks a significant advancement in NT1 treatment, providing a holistic approach rather than targeting individual symptoms.
Reuters Reuters
Michigan eases lettuce advice as state health department says cyclosporiasis reports decline

Michigan eases lettuce advice as state health department says cyclosporiasis reports decline

Aug 6 (Reuters) - Michigan health officials on Thursday advised residents to resume eating lettuce and salad greens, citing a slowdown in new cyclosporiasis infections, after reporting 12,485 cases linked to the outbreak, up 267 cases from a day earlier.